At Innocan, we are committed to revolutionizing chronic pain treatment through advanced scientific innovation. Our unique injectable delivery platform, LPT-CBD, utilizes liposome technology to deliver precise doses of synthetic cannabidiol (CBD) with controlled release.

Advantages of LPT-CBD

LPT-CBD stands out with several key benefits over traditional opioid therapies, standard CBD applications and other treatments: 

• High Bioavailability: Nearly 100% bioavailability of synthetic CBD for maximum therapeutic effect. 
• Precise Dosing & Prolonged Release: Ensures exact dosing with sustained release, maintaining therapeutic levels for extended periods. 
• Extended Efficacy: A single injection lasts up to 4 weeks, replacing the need for twice-daily oral consumption. 

How It Works 

Liposomes are spherical carriers made of lipid layers, enhancing drug performance by transporting therapeutic agents through the vascular system. They are biocompatible and non-toxic.

Administration & Distribution 

LPT-CBD is administered subcutaneously, where the liposomes remain under the skin, allowing for slow, controlled release of cannabidiol to the blood and target organs. This method ensures superior bioavailability, outperforming oral, sublingual, or inhalation delivery methods.

Proven Efficacy & Safety 

In comprehensive animal trials, LPT-CBD has demonstrated safety and efficacy across various chronic pain conditions. These trials, conducted under rigorous standards, highlight the potential of our technology to significantly improve treatment outcomes. 

Intellectual Property 

Our commitment to innovation is reflected in our robust intellectual property portfolio. To date, we have been granted 3 patents, with over 34 additional patents pending across 11 patent families in the field of drug delivery and wellness. 

At Innocan, our dedication to scientific advancement drives us to develop therapies that enhance patient care and quality of life.